Harnessing J&J's Power to turn early stage science into patient solutions




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Harnessing J&J's Power to turn early stage science into patient solutions
Released on: August 15, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    ‘Our CSO, Paul Stoffells has a great quote which is our call to action ‘’To save one life is significant, to save millions of lives is addictive, so come get addicted with me’’, so when we go out there that’s what we are trying to do.
  • Summary
  • Transcript
  • Participants
  • Company
‘Our CSO, Paul Stoffells has a great quote which is our call to action ‘’To save one life is significant, to save millions of lives is addictive, so come get addicted with me’’, so when we go out there that’s what we are trying to do. Getting everyone addicted to progressing great science to the patient’ Melinda Richter, Head of Janssen Labs During BIO 2014 in San Diego, PharmaVentures’ Adrian Dawkes chatted with Melinda and discovered how Janssen Labs and Johnson & Johnson Innovation are setting about creating patient solutions that would not have otherwise existed.
‘Our CSO, Paul Stoffells has a great quote which is our call to action ‘’To save one life is significant, to save millions of lives is addictive, so come get addicted with me’’, so when we go out there that’s what we are trying to do. Getting everyone addicted to progressing great science to the patient’ Melinda Richter, Head of Janssen Labs During BIO 2014 in San Diego, PharmaVentures’ Adrian Dawkes chatted with Melinda and discovered how Janssen Labs and Johnson & Johnson Innovation are setting about creating patient solutions that would not have otherwise existed.
Melinda Richter
Janssen Labs
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas, including: attention deficit hyperactivity disorder (ADHD), general medicine (acid reflux disease, infectious diseases), mental health (bipolar I disorder, schizophrenia), neurologics (Alzheimer’s disease, epilepsy, migraine prevention and treatment), pain management, and women’s health. Our ultimate goal is to help people live healthy lives. We have produced and marketed many first-in-class prescription medications and are poised to serve the broad needs of the healthcare market – from patients to practitioners, from clinics to hospitals. Headquartered in Titusville, New Jersey, Janssen is named after Dr. Paul Janssen, a leading Belgian researcher, pharmacologist, and general practitioner. Dr. Janssen led a group of researchers to discover a medicine that helped change the way mental health patients were treated. His company, Janssen Pharmaceutica, joined the Johnson & Johnson family of companies in 1961. Our company remains guided by Dr. Janssen’s values of excellence and innovation.